<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30049185</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">2476-762X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>19</Volume>                    <Issue>7</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                        <Day>27</Day>                    </PubDate>                </JournalIssue>                <Title>Asian Pacific journal of cancer prevention : APJCP</Title>                <ISOAbbreviation>Asian Pac. J. Cancer Prev.</ISOAbbreviation>            </Journal>            <ArticleTitle>Relationships between Reproductive Risk Factors for Breast Cancer and Tumor Molecular Subtypes</ArticleTitle>            <Pagination>                <MedlinePgn>1767-1770</MedlinePgn>            </Pagination>            <Abstract>                <AbstractText>Background: Due to wide clinical differences in the various pathological types of breast cancer and also closeassociations between disease prognosis and molecular subtypes, relationships of the latter with traditional risk factorshave been suggested. Hence, the present study aimed to assess any associations. Methods: This bi-center cross-sectionalstudy was performed on 800 consecutive women with known breast cancer referred to two Comprehensive Cancer Centersin Tehran between 2006 and 2016. Baseline information related to reproductive risk profiles as well as pathologicaltumor diagnosis and molecular subtypes determined using immunohistochemical analysis by immune-staining forER, PR, and HER2 molecules were collected by reviewing hospital records. Results: Of 800 samples included forimmunohistochemical analysis, 314 (39.3%) were diagnosed as of Luminal A subtype, 107 (13.4%) as Luminal Bsubtype, 153 (19.1%) as HER-2 over-expressing, and 226 (28.3%) as triple negative. Among all reproductive riskfactors initially assessed, young age was associated with HER-2 over-expression, greater tumor size and a history ofabortion with the luminal B subtype, lower age at pregnancy with the luminal A subtype, and lower gravidity anda shorter duration of breastfeeding with the triple negative subtype. Conclusion: Each molecular subtype of breastcancer in our population may be associated with specific reproductive risk factors.</AbstractText>                <CopyrightInformation>Creative Commons Attribution License</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nafissi</LastName>                    <ForeName>Nahid</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, Iran University of Medical Science, Rasool-Akram Hospital, Tehran, Iran. Email: s.hamzah.mousavie@gmail.com</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Faraji</LastName>                    <ForeName>Maryam</ForeName>                    <Initials>M</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Hosseini</LastName>                    <ForeName>Mostafa</ForeName>                    <Initials>M</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Shojaee</LastName>                    <ForeName>Leyla</ForeName>                    <Initials>L</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Ziaei</LastName>                    <ForeName>Fatane</ForeName>                    <Initials>F</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Akbari</LastName>                    <ForeName>Mohamad Esmaiel</ForeName>                    <Initials>ME</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Mousavie</LastName>                    <ForeName>Seyed Hamzeh</ForeName>                    <Initials>SH</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Thailand</Country>            <MedlineTA>Asian Pac J Cancer Prev</MedlineTA>            <NlmUniqueID>101130625</NlmUniqueID>            <ISSNLinking>1513-7368</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2011 Nov;130(2):587-97</RefSource>                <PMID Version="1">21667121</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2008 Oct 1;113(7):1521-6</RefSource>                <PMID Version="1">18726992</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Womens Health (Lond). 2016 Jan;12(1):103-19</RefSource>                <PMID Version="1">26756229</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast J. 2009 Sep-Oct;15(5):562-3</RefSource>                <PMID Version="1">19671107</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2011 Jun 27;13(3):212</RefSource>                <PMID Version="1">21787441</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Springerplus. 2015 Sep 17;4:508</RefSource>                <PMID Version="1">26405628</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2012 Sep;23(9):2435-41</RefSource>                <PMID Version="1">22328736</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gan To Kagaku Ryoho. 2016 Mar;43(3):290-3</RefSource>                <PMID Version="1">27067844</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2003;5(6):303-4</RefSource>                <PMID Version="1">14580246</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43</RefSource>                <PMID Version="1">17372238</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2015 Oct 16;34(42):5309-16</RefSource>                <PMID Version="1">25703331</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Virchows Arch. 2014 Jul;465(1):1-14</RefSource>                <PMID Version="1">24878755</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2008 May;109(1):123-39</RefSource>                <PMID Version="1">17578664</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast. 2013 Jun;22(3):344-50</RefSource>                <PMID Version="1">22981738</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Exp Med Biol. 2013;779:35-54</RefSource>                <PMID Version="1">23288634</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">Reproductive</Keyword>            <Keyword MajorTopicYN="Y">breast cancer</Keyword>            <Keyword MajorTopicYN="Y">tumor marker</Keyword>            <Keyword MajorTopicYN="Y">HER2</Keyword>            <Keyword MajorTopicYN="Y">tumor molecular subtypes</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>7</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30049185</ArticleId>            <ArticleId IdType="doi">10.22034/APJCP.2018.19.7.1767</ArticleId>            <ArticleId IdType="pmc">PMC6165646</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>